Equities analysts expect that TherapeuticsMD Inc (NASDAQ:TXMD) will report sales of $4.10 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for TherapeuticsMD’s earnings, with the lowest sales estimate coming in at $3.94 million and the highest estimate coming in at $4.30 million. TherapeuticsMD reported sales of $3.99 million during the same quarter last year, which would suggest a positive year over year growth rate of 2.8%. The firm is scheduled to announce its next earnings results on Tuesday, May 1st.
On average, analysts expect that TherapeuticsMD will report full-year sales of $30.28 million for the current fiscal year, with estimates ranging from $18.42 million to $59.11 million. For the next fiscal year, analysts anticipate that the business will post sales of $181.99 million per share, with estimates ranging from $122.86 million to $275.46 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The company’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS.
Institutional investors and hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new stake in TherapeuticsMD in the 3rd quarter valued at $528,000. California State Teachers Retirement System raised its stake in TherapeuticsMD by 4.5% in the 4th quarter. California State Teachers Retirement System now owns 261,142 shares of the company’s stock valued at $1,577,000 after acquiring an additional 11,317 shares during the period. BlackRock Inc. raised its stake in TherapeuticsMD by 29.7% in the 4th quarter. BlackRock Inc. now owns 14,431,862 shares of the company’s stock valued at $87,169,000 after acquiring an additional 3,307,477 shares during the period. Nexthera Capital LP bought a new stake in TherapeuticsMD in the 4th quarter valued at $3,191,000. Finally, OppenheimerFunds Inc. raised its stake in TherapeuticsMD by 10.8% in the 4th quarter. OppenheimerFunds Inc. now owns 1,634,080 shares of the company’s stock valued at $9,870,000 after acquiring an additional 158,943 shares during the period. Institutional investors and hedge funds own 73.31% of the company’s stock.
Shares of NASDAQ TXMD traded down $0.14 during trading hours on Monday, hitting $5.71. The company had a trading volume of 1,253,017 shares, compared to its average volume of 2,163,830. The company has a market cap of $1,265.94, a PE ratio of -15.43 and a beta of 1.36. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $7.01.
WARNING: This piece was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/04/21/therapeuticsmd-inc-txmd-expected-to-post-quarterly-sales-of-4-10-million.html.
TherapeuticsMD, Inc is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.